Bristol-Myers Squibb Company Joins Multiple Myeloma Research Foundation (MMRF) to Advance Personalized Medicine Approaches for Multiple Myeloma

Published: Dec 14, 2012

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) today announced that Bristol-Myers Squibb has joined the MMRF pre-competitive consortium (PCC) to discover and accelerate new approaches to treating multiple myeloma through the organization’s Personalized Medicine Initiative (PMI).

Back to news